| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -CAD 44.1M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $128.2M | Trading Days | 128 |
| 52W High | 6.30 |
| 52W Low | 1.59 |
| % Off High | −74.44% |
| Ann. Volatility (1Y) | 89.66% | Ann. Volatility (3Y) | 89.66% |
| Sharpe (1Y) | −2.35 | Sharpe (3Y) | −2.35 |
| Max Drawdown (1Y) | −73.03% | Max Drawdown (3Y) | −73.03% |
| YTD | −73.03% | Since inception | −73.03% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PEPG | PepGen Inc. | $126.6M | — |
| PMN | ProMIS Neurosciences Inc. | $130.2M | — |
| GNLX | GENELUX Corp | $130.9M | — |
| UNCY | Unicycive Therapeutics, Inc. | $131.9M | — |
| MIST | Milestone Pharmaceuticals Inc. | $133.2M | — |
| HURA | TuHURA Biosciences, Inc./NV | $135.6M | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $120.7M | — |
| ANIX | Anixa Biosciences Inc | $119.8M | — |
| AARD | Aardvark Therapeutics, Inc. | $140.1M | — |
| ADCT | ADC Therapeutics SA | $141.2M | — |
| CNTN | Canton Strategic Holdings, Inc. |
| $142.4M |
| — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $114.5M | — |
